Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

Study acronym: SEMAPSO
StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Hospital Universitario Dr. Jose E. Gonzalez
11 trials monitored
See all monitored trials
Diabetes
5,141 trials monitored
See 246 trials at risk
Obesity
3,909 trials monitored
See 165 trials at risk
Type 2 Diabetes
2,257 trials monitored
See 120 trials at risk
and 1 more disease
This study will evaluate the effects of oral semaglutide in combination with topical corticosteroid/calcipotriol on clinical outcomes and metabolic inflammation in patients with plaque psoriasis and overweight/obesity and/or type 2 diabetes mellitus. A total of 62 participants will be randomized to receive either semaglutide plus topical corticosteroid/calcipotriol or placebo plus topical corticosteroid/calcipotriol for 12 weeks. Clinical efficacy will be assessed using the Psoriasis Area and Severity Index (PASI), and quality of life will be evaluated using DLQI, PROMIS-29, and EQ-5D-5L. Systemic inflammatory markers will also be measured to assess metabolic inflammation.
Trial Details
NCT Number NCT07401992
Lead Sponsor Hospital Universitario Dr. Jose E. Gonzalez
Conditions
(from sponsor)		 Psoriasis (PsO), Obesity & Overweight, Diabetes Mellitus - Type 2
Related terms Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity, Overweight, Psoriasis
Enrollment 62 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov